| Patents for A61P 13 - Drugs for disorders of the urinary system (56,135) |
|---|
| 08/01/2002 | US20020102641 Oncogenic osteomalacia-related gene 1 |
| 08/01/2002 | US20020102619 Heparanase specific molecular probes and their use in research and medical applications |
| 08/01/2002 | US20020102535 Nucleic acid molecules and polypeptides for immune modulation |
| 08/01/2002 | DE10101307A1 Fumarsäurederivate als NF-kappaB-Inhibitor Fumaric acid derivatives as NF-kappaB inhibitor |
| 08/01/2002 | CA2436139A1 Methods of inducing organ transplant tolerance and correcting hemoglobinopathies |
| 08/01/2002 | CA2435829A1 Trisubstituted carbocyclic cyclophilin binding compounds and their use |
| 08/01/2002 | CA2435047A1 Constitutively desensitized g protein-coupled receptors |
| 08/01/2002 | CA2434320A1 Chemokines as adjuvants of immune response |
| 08/01/2002 | CA2426102A1 Method of diagnosing and treating cartilaginous disorders |
| 07/31/2002 | EP1227105A1 Ghsr ligand polypeptides and dnas thereof |
| 07/31/2002 | EP1227090A1 Amine derivatives |
| 07/31/2002 | EP1227085A1 Process for producing optically active naphthalene derivative and optical resolver therefor |
| 07/31/2002 | EP1226822A2 Promoter for production of nitric oxide or nitric oxide synthase, and cosmetic or pharmaceutical composition comprising the same |
| 07/31/2002 | EP1226435A1 Axor35, a g-protein coupled receptor |
| 07/31/2002 | EP1226279A1 Modulation of neuroendocrine differentiation by protein 25.1 |
| 07/31/2002 | EP1226247A1 Human gpr27-like g-protein coupled receptor polypeptide and polynucleotide sequences |
| 07/31/2002 | EP1226239A1 Methods of producing differentiated progenitor cells and lineage-defective embryonic stem cells |
| 07/31/2002 | EP1226159A1 Substituted dipeptides having nos inhibiting activity |
| 07/31/2002 | EP1226155A2 18-nor-steroids as selectively active estrogens |
| 07/31/2002 | EP1226151A2 Gene expression directed by a super-psa promoter |
| 07/31/2002 | EP1226150A1 Tadg-15: an extracellular serine protease overexpressed in carcinomas |
| 07/31/2002 | EP1226137A1 Phenyl- and pyridyl-tetrahydro-pyridines having tnf inhibiting activity |
| 07/31/2002 | EP1226132A1 Nonpeptide substituted benzothiazepines as vasopressin antagonists |
| 07/31/2002 | EP1226131A2 Isoxazolecarboxamide derivatives |
| 07/31/2002 | EP1226126A1 Pyrimidine derivatives |
| 07/31/2002 | EP1226124A1 Heterocyclically substituted benzoylguanidine, method for the production thereof, the use thereof as a medicament or means of diagnosis and a medicament containing the same |
| 07/31/2002 | EP1226122A1 Bicyclic vasopressin agonists |
| 07/31/2002 | EP1225956A1 Method and compositions for administering taxanes orally to human patients |
| 07/31/2002 | EP1225915A2 Prevention and treatment of autoimmune disease with luminally administered polyclonal antibodies |
| 07/31/2002 | EP1225909A2 Fibroblast growth factor-5 (fgf-5) is a tumor associated t-cell antigen |
| 07/31/2002 | EP1225901A2 Uses and compositions for treating platelet-related disorders using anagrelide |
| 07/31/2002 | EP1225900A1 Use of dipyridamole or mopidamol in the manufacture of a medicament for the treatment and prevention of fibrin-dependent microcirculation disorders |
| 07/31/2002 | EP1225894A1 Fab i inhibitors |
| 07/31/2002 | EP0708656B1 Immunogenic lhrh peptide constructs and synthetic universal immune stimulators for vaccines |
| 07/31/2002 | CN1361783A Thiazoloderivatives and pharmaceutical compositions containing them |
| 07/31/2002 | CN1361782A Substituted imidazothiazoles as antidepressant agents |
| 07/31/2002 | CN1361781A Oxazinocarbazoles for the treatment of CNS diseases |
| 07/31/2002 | CN1361773A Substituted 3-pyridyl-4-arylpyrroles, and related therapeutic and prophylactic methods |
| 07/31/2002 | CN1361767A 1,4,5,6-tetrahydropyrimidine derivative as a vitronectin inhibitor |
| 07/31/2002 | CN1361690A Pharmaceutical and nutritional compositions containing essential fatty acids and homocysteine-lowering agents |
| 07/31/2002 | CN1361687A Phosphate transport inhibitors |
| 07/31/2002 | CN1361685A Sustained release compositions, process for producing the same and use thereof |
| 07/31/2002 | CN1361677A Oral pharmaceutical compositions containing taxanes and methods of treatment employing the same |
| 07/31/2002 | CN1360925A Chinese herbal medicine composition for treating chronic renal adynamia |
| 07/31/2002 | CN1360924A Chinese herb medicine composition for treating glomerulonephritis |
| 07/31/2002 | CN1088375C Medicinal tea for invigorating kidney and replenishing vital essence |
| 07/31/2002 | CA2369462A1 Nicotinamide acids, amides, and their mimetics active as inhibitors of pde4 isozymes |
| 07/30/2002 | US6426413 Inhibitors of caspases |
| 07/30/2002 | US6426402 Respiratory system disorders; rheumatic diseases |
| 07/30/2002 | US6426344 Aryl and heteroaryl substituted indolealkanoic acids |
| 07/30/2002 | US6426341 Treatment for diabetic complications |
| 07/30/2002 | US6426199 Isolated, purified nucleic acid detecting or isolating mutant forms of the dna molecules. |
| 07/25/2002 | WO2002057460A2 Polynucleotides encoding human phosphatases |
| 07/25/2002 | WO2002057453A2 Polypetides and nucleic acids encoding same |
| 07/25/2002 | WO2002057452A2 Human proteins, polynucleotides encoding them and methods of using the same |
| 07/25/2002 | WO2002057413A2 Peptides for activation and inhibition of delta pkc |
| 07/25/2002 | WO2002057298A2 C-terminal modified oxamyl dipeptides as inhibitors of the ice/ced-3 family of cysteine proteases |
| 07/25/2002 | WO2002057267A1 Compounds specific to adenosine a1, a2a, and a3 receptor and uses thereof |
| 07/25/2002 | WO2002057265A1 Compounds substituted with bicyclic amino groups |
| 07/25/2002 | WO2002057261A2 Diaminothiazoles and their use as inhibitors of cyclin-dependent kinase |
| 07/25/2002 | WO2002057259A2 Pyrazole compounds useful as protein kinase inhibitors |
| 07/25/2002 | WO2002057242A2 Urea derivatives as integrin alpha 4 antagonists |
| 07/25/2002 | WO2002057237A1 Hetero-tricyclic compounds having substituted amino groups |
| 07/25/2002 | WO2002057230A1 Il-8 receptor antagonists |
| 07/25/2002 | WO2002057222A2 Thiol-based naaladase inhibitors |
| 07/25/2002 | WO2002057211A1 Symmetrically disubstituted aromatic compounds and pharmaceutical compositions for inhibiting poly (adp-ribose) glycohydrolase, and methods for their use |
| 07/25/2002 | WO2002032901A3 Bridged piperazine derivatives |
| 07/25/2002 | WO2002032422A3 Ep4 receptor inhibitors to treat rheumatoid arthritis |
| 07/25/2002 | WO2002020615A3 Antibody and/or chemokine constructs which bind to a chemokine receptor and their use in immunological disorders |
| 07/25/2002 | WO2002018379A3 7-oxo pyridopyrimidines |
| 07/25/2002 | WO2002014320A3 Novel substituted diaryl azepine derivatives as integrin ligands |
| 07/25/2002 | WO2002004496A3 Fimh adhesin proteins and methods of use |
| 07/25/2002 | WO2001092273A3 Benzenedicarboxylic acid derivatives |
| 07/25/2002 | US20020099222 Heterocyclically substituted benzoylguanidines, process for their preparation, their use as medicaments or diagnostics, and medicaments comprising them |
| 07/25/2002 | US20020099096 Useful for oral testosterone replacement therapy, male contraception, maintaining sexual desire in women, treating prostate cancer and imaging prostate cancer |
| 07/25/2002 | US20020099071 Protein tyrosine kinase and protein serin/threonine kinase inhibitory activity; anticancer agents; treating chemotherapy induced alopecia |
| 07/25/2002 | US20020098201 Novel myxoma genes for immune modulation |
| 07/25/2002 | US20020098197 Hla binding peptides and their uses |
| 07/25/2002 | CA2434939A1 Urea derivatives as integrin alpha 4 antagonists |
| 07/25/2002 | CA2434636A1 Symmetrically disubstituted aromatic compounds and pharmaceutical compositions for inhibiting poly (adp-ribose) glycohydrolase, and methods for their use |
| 07/25/2002 | CA2434296A1 Diaminothiazoles and their use as inhibitors of cyclin-dependent kinase |
| 07/25/2002 | CA2433879A1 C-terminal modified oxamyl dipeptides as inhibitors of the ice/ced-3 family of cysteine proteases |
| 07/25/2002 | CA2433313A1 Polypetides and nucleic acids encoding same |
| 07/25/2002 | CA2432041A1 Polynucleotides encoding human phosphatases |
| 07/25/2002 | CA2430634A1 Proteins, polynucleotides encoding them and methods of using the same |
| 07/25/2002 | CA2430577A1 Compounds specific to adenosine a1, a2a, and a3 receptor and uses thereof |
| 07/24/2002 | EP1225183A2 Human G-protein coupled receptor |
| 07/24/2002 | EP1224941A2 Antithrombin III used in diseases caused by angiogenesis |
| 07/24/2002 | EP1224932A1 Drugs inhibiting cell death |
| 07/24/2002 | EP1224862A1 Model animal of mesangial cell proliferative nephritis |
| 07/24/2002 | EP1224322A2 Gene sequence variations with utility in determining the treatment of disease |
| 07/24/2002 | EP1224281A1 37 human secreted proteins |
| 07/24/2002 | EP1224218A1 Dna encoding human alpha1g-c t-type calcium channel |
| 07/24/2002 | EP1224210A2 Basic monocyclic compounds having nk2 antagonist action, processes for their preparation, and formulations containing them |
| 07/24/2002 | EP1224209A1 10 human secreted proteins |
| 07/24/2002 | EP1224201A1 32 human secreted proteins |
| 07/24/2002 | EP1224200A1 Tissue plasminogen activator-like protease |
| 07/24/2002 | EP1224199A1 Transgenic mice containing trp gene disruptions |
| 07/24/2002 | EP1224187A2 Certain alkylene diamine-substituted heterocycles |
| 07/24/2002 | EP1224183A2 Heterocyclic sodium/proton exchange inhibitors and method |